Ann: Invex Granted European Orphan Drug Designation for TBI, page-8

People I don’t understand what has happened here and how this has massively de-risked this investment. We are no longer a one trick pony, and relying on one indication. This factor alone steered a lot of investors away.

we should see alot of new investors waiting on the sidelines for this news to jump on board IMO.

it also offers enormous leverage on a huge buyout by a big pharma.

also previous reports with MST etc with DCF valuation can more than triple by almost quadrupling our potential TAM, albeit it’s early stages, this news is huge.

let’s wait for this news to sink in to the overall market